Annual report [Section 13 and 15(d), not S-K Item 405]

Stockholders Equity - Schedule of Outstanding Compensation Related Warrants to Purchase Common Stock (Details)

v3.25.1
Stockholders Equity - Schedule of Outstanding Compensation Related Warrants to Purchase Common Stock (Details) - Common Stock [Member]
 12 Months Ended
Dec. 31, 2024
$ / shares
shares
Schedule of Outstanding Compensation Related Warrants to Purchase Common Stock [Line Items]  
Number of Shares of Common Stock Underlying Warrants 25,298
Private Warrants [Member]  
Schedule of Outstanding Compensation Related Warrants to Purchase Common Stock [Line Items]  
Issuance Date Nov. 27, 2017 [1]
Expiration Date [1]
Exercise Price Per Share | $ / shares [1]
Number of Shares of Common Stock Underlying Warrants 298 [1]
Landlord Warrants [Member]  
Schedule of Outstanding Compensation Related Warrants to Purchase Common Stock [Line Items]  
Issuance Date Mar. 15, 2024 [2]
Expiration Date Jan. 28, 2027 [2]
Exercise Price Per Share | $ / shares $ 50 [2]
Number of Shares of Common Stock Underlying Warrants 25,000 [2]
[1] In November 2017, BiomX Israel issued 298 warrants to its founders. The warrants were fully vested at their grant date and will expire immediately prior to a consummation of an M&A transaction. The warrants did not expire as a result of the Recapitalization Transaction and have no exercise price. The Merger Agreement as described in note 1D does not apply for such M&A transaction as defined in the grant agreement.
[2] See Note 5